英科医疗科技股份有限公司 2023 年半年度报告全文 2023 年半年度报告 1 第一节 重要提示、目录和释义 公司负责人刘方毅、主管会计工作负责人冯杰及会计机构负责人(会计主 管人员)焦裕发声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 2 目录 3 备查文件目录 二、载有法定代表人签名的 2023 年半年度报告文本件。 4 | --- | --- | --- | |-----------------------------------------------|-------|----------------------------------------------------| | 释义项 | 指 | 释义内容 | | 英科医疗、英科医疗公司、公司、本 公司、母公司 | 指 | 英科医疗科技股份有限公司 | | 山东英科 | 指 | 山东英科医疗制品有限公司 | | 上海英科 | 指 | 上海英科医疗用品有限公司 | | 英科心电图 | 指 | 上海英科心电图医疗产品有限公司 | | 上海英恩 | 指 | 上海英恩国际贸易有限公司 | | 江苏英科 ...

英科医疗科技股份有限公司 独立董事：王 洋 吴晓辉 向 静 独立董事关于第三届董事会第十六次（定期）会议 报告期内，公司与关联方之间的资金往来属于正常的经营性关联 交易的资金往来，交易程序合法，定价公允，没有损害公司和全体股 东的利益。 二、关于公司对外担保情况的说明及独立意见 经核查，报告期内，公司不存在向控股股东、实际控制人及其关 联方提供担保的情形，也不存在违反决策程序对外提供担保的情况。 报告期内，公司能够严格遵循有关法律法规及规范性文件以及 《公司章程》关于对外担保的有关规定，严格控制对外担保风险。 相关事项的独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往 来、对外担保的监管要求》（证监会公告〔2022〕26 号）《上市公司 独立董事规则》《英科医疗科技股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，我们作为英科医疗科技股份有限公司（以下 简称"公司"）的独立董事，基于独立判断的立场，本着对公司、全体 股东和投资者负责的态度，秉持实事求是的原则，对公司截至 2023 年 6 月 30 日控股股东及其他关联方是否占用公司资金的情况、公司 对外担保情况进行了认真细致的 ...

| 非经营性资金占用 | 资金占 用方名 | 占用方与上市 公司的关联关 | 上市公司核 算的会计科 | 年期初占 2023 用资金余额 | 2023上半年占用累计 发生金额（不含利 | 上半年偿还 2023 累计发生金额 | 上半年占 2023 用资金余额 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 称 | 系 | 目 | | 息） | | | | | | 控股股东、实际控 制人及其附属企业 | | | | | 不适用 | | | | | | 小 计 | | | | | 不适用 | | | | | | 前控股股东、实际 控制人及其附属企 | | | | | 不适用 | | | | | | 业 | | | | | | | | | | | 小 计 | | | | | 不适用 | | | | | | 其他关联方及其附 | | | | | 不适用 | | | | | | 属企业 | | | | | | | | | | | 小 计 | | | | | 不适用 | | | | | | 总 计 | ...

英科医疗科技股份有限公司 关于为全资子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2023年 4月 27 日、2023 年 5 月 23 日分别召开的第三届董事会第十三次（定期） 会议、第三届监事会第十二次（定期）会议以及 2022 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的 议案》。为保证公司资金需求，公司及子公司拟向银行等金融机构申 请综合授信的额度以及金融衍生品交易风险限额的总额（以下简称 "授信额度"）不超过 215 亿元人民币，对其担保总额不超过 215 亿 元人民币，授权期限自公司 2022 年度股东大会审议通过之日起至下 一年度股东大会召开时止，具体内容详见刊登于巨潮资讯网 （www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额度 及担保事项的公告》《2022 年度股东大会决议公告》(公告编号:2023- 029、2023-040)。 证券代码：300677 证券简称：英科医疗 公告编号：2023-077 一、担保事项概述 ...

| 证券代码：300677 | 证券简称：英科医疗 公告编号：2023-076 | | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | 英科医疗科技股份有限公司 关于英科转债 2023 年付息公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 英科转债将于 2023 年 8 月 16 日按面值支付第四年利息，每 10 张英科转债（面值 1,000.00 元）利息为 33.00 元（含税）。 7. 下一付息期起息日：2023 年 8 月 16 日 英科医疗科技股份有限公司（以下简称"公司"）于 2019 年 8 月 16 日公开发行的可转换公司债券（以下简称"英科转债"）将于 2023 年 8 月 16 日支付自 2022 年 8 月 16 日至 2023 年 8 月 15 日期间 的利息。根据《山东英科医疗用品股份有限公司创业板公开发行可转 换公司债券募集说明书》（以下简称"募集说明书"）有关条款的规 定，现将有关事项公告如下： 一、债券基本情况 2. 债权登记日：2023 年 8 月 15 日 3. 本次付息期间 ...

证券代码：300677 证券简称：英科医疗 英科医疗科技股份有限公司 投资者关系活动记录表 编号：2023-001 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他 参与单位名称 投资者线上提问 时间 2023 年 5 月 19 日 15:00-17:00 地点 中国证券报·中证网"路演中心"平台 英科医疗业绩说明会页面 （https://www.cs.com.cn/roadshow/yjsmh/300677/index.html） 上市公司接待人员 总经理、董事 陈琼 独立董事 王洋 董事会秘书 李斌 财务总监 冯杰 证券事务代表 宋且未、刘文静 投资者关系活动主要 内容介绍 1、2022 年公司产销量分别是多少？ 回复：尊敬的投资者，您好！根据行业分类，公司 2022 年度 一次性 PVC 手套和丁腈手套的生产量为 455.60 亿只，销售量为 463.82 亿只；轮椅产品的生产量为 66.41 万台，销售量为 63.90 万 台；冷热敷产品的生产量为 1,425.94 万片，销售量 1,430.82 万片； 电极片产品 ...

证券代码：300677 证券简称：英科医疗 公告编号：2023-039 英科医疗科技股份有限公司 关于举行 2022 年度暨 2023 年第一季度 英科医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在巨潮资讯网（www.cninfo.com.cn）发布了《2022 年年度 报告》《2022 年年度报告摘要》《2023 年一季度报告》。为便于广大投 资者更深入、全面地了解公司情况，公司定于 2023 年 5 月 19 日（星 期五）15:00-17:00 在中国证券报·中证网"路演中心"平台举行 2022 年度暨 2023 年第一季度业绩网上说明会。 本次说明会将采用网络远程方式举行，投资者可登录中国证券 报·中证网"路演中心"平台（https://www.cs.com.cn/roadshow），点 击 " 业绩说明会 "栏目， 进 入 公 司 本次业绩说明会 页 面 （https://www.cs.com.cn/roadshow/yjsmh/300677/index.html），或扫描 下方二维码，进入活动页面，参与本次业绩网上说明会互动。 出席本次说明会的人员有：公司总经理陈琼 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,572,919,050, a decrease of 31.25% compared to ¥2,287,865,174 in the same period last year[14] - The net profit attributable to shareholders was a loss of ¥153,056,715, representing a decline of 283.32% from a profit of ¥83,493,070 in the previous year[14] - Basic and diluted earnings per share were both -¥0.23, a decrease of 276.92% compared to ¥0.13 in the previous year[14] - The company reported a significant decline in net profit and cash flow, indicating challenges in operational performance[14] - Total revenue for Q1 2023 was approximately ¥1.57 billion, a decrease of 31.25% compared to ¥2.29 billion in Q1 2022[27] - The net profit for Q1 2023 was a loss of RMB 146,768,893.00, compared to a profit of RMB 79,471,291.00 in Q1 2022, reflecting a significant decline in profitability[51] Cash Flow and Operating Activities - The net cash flow from operating activities was a negative ¥174,585,120, down 141.90% from ¥416,703,728 in the same period last year[14] - Net cash flow from operating activities for Q1 2023 was -¥174.59 million, a decline of 141.90% compared to ¥416.70 million in Q1 2022, primarily due to a decrease in sales collections[27] - The company received cash related to operating activities amounting to ¥1,608,049,667, down from ¥2,183,935,286, a decrease of approximately 26.3%[40] - In the first quarter, the cash flow from operating activities was 1,383,659,242.00 CNY, a decrease from 1,977,957,759.00 CNY in the previous period[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥22,432,730,237, an increase of 4.44% from ¥21,478,748,819 at the end of the previous year[14] - The company’s total liabilities increased to RMB 6,527,111,500.00 from RMB 5,429,493,543.00, marking an increase of approximately 20.2%[49] - The equity attributable to shareholders decreased by 0.95% to ¥15,656,405,151 from ¥15,806,329,512 at the end of the previous year[14] - The company’s total equity as of March 31, 2023, was RMB 15,905,618,737.00, down from RMB 16,049,255,276.00 at the beginning of the year[49] Financing Activities - Cash flow from financing activities increased by 373.82% to ¥1.44 billion from ¥304.59 million, mainly due to an increase in bank loans during the reporting period[27] - Net cash flow from financing activities was ¥1,443,194,634, a substantial increase from ¥304,588,408, indicating strong financing support[40] Expenses and Costs - The total operating costs for Q1 2023 were RMB 1,744,533,179.00, down from RMB 2,186,961,202.00 in Q1 2022, indicating a reduction of approximately 20.2%[49] - The company experienced a 48.11% reduction in selling expenses, which fell to ¥50.85 million from ¥98.01 million, primarily due to decreased export costs[27] - Financial expenses rose by 129.55% to ¥43.59 million from ¥18.99 million, mainly due to increased exchange losses during the reporting period[27] - Research and development expenses for Q1 2023 were RMB 63,880,401.00, slightly down from RMB 69,568,207.00 in the previous year, showing a decrease of about 8.3%[51] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 72,471, with the largest shareholder holding 35.05%[28] - The company has repurchased a total of 14,002,107 shares, accounting for 2.1223% of the total share capital, with a total transaction amount of RMB 314,419,803.15[45] - The company plans to use between RMB 250 million and RMB 500 million for share repurchase to implement employee stock ownership plans and/or equity incentives[45] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - There is no indication of mergers or acquisitions in the current financial report[14] - The company plans to purchase liability insurance for its directors and senior management to enhance risk management and protect investor interests[44] - The impact of exchange rate changes on cash and cash equivalents was a loss of 78,944,203.00 CNY, compared to a loss of 26,412,769.00 CNY in the previous period[55] - The company’s first quarter report is unaudited[53]

Market Demand and Competition - In 2022, the overall market demand for medical gloves significantly declined due to excessive inventory from downstream customers, leading to a shift from supply shortage to oversupply [6]. - The company faced intense price competition, resulting in a decrease in product sales prices and a corresponding decline in overall sales revenue [6]. - The U.S. reinstated additional tariffs on nitrile gloves, with medical-grade gloves at 7.5% and industrial-grade gloves at 25%, impacting the company's exports to the U.S. market [6]. - The company reported that most glove manufacturers faced losses and significant revenue declines in 2022 due to long-cycle adjustments in the industry [6]. Financial Performance - The company achieved operating revenue of ¥6,613,814,056, a decrease of 59.27% compared to the previous year [48]. - Net profit attributable to shareholders was ¥629,070,097, down 91.53% year-on-year [48]. - The net cash flow from operating activities was ¥1,065,469,515, a decline of 87.73% compared to the previous year [48]. - The total assets at the end of the reporting period amounted to ¥21,478,748,819, an increase of 4.14% year-on-year [48]. - The personal protective equipment segment accounted for 90.80% of total revenue, generating ¥6,005,052,667, a decrease of 62.01% year-on-year [51]. - The company's revenue for the medical device sector reached ¥6,613,814,056, a decrease of 59.27% compared to the previous year, with a gross margin of 13.13% [73]. - Personal protective equipment sales amounted to ¥6,005,052,667, reflecting a 62.01% decline year-over-year, with a gross margin of 13.07% [73]. - Domestic sales were ¥1,135,172,630, down 54.15% year-over-year, while overseas sales totaled ¥5,478,641,426, a decrease of 60.20% [73]. Production and Capacity - The annual production capacity of disposable non-latex gloves reached 75 billion units, with 45 billion units for nitrile gloves and 30 billion units for PVC gloves [37]. - The company has established four major production bases in China, enhancing its market presence and operational efficiency [140]. - The company has developed a third-generation fully automatic production line for nitrile gloves, achieving a production yield rate of over 99% and significantly reducing energy consumption [168]. Research and Development - The total R&D investment amounted to ¥252,323,095, representing 3.82% of operating revenue, an increase from 2.25% in 2021 [93]. - The number of R&D personnel decreased by 17.15% to 952, with the proportion of R&D personnel in the total workforce dropping to 10.79% [93]. - The company has filed 65 patents and received 21 authorizations, continuously improving its R&D capabilities [170]. - The company launched new products including diamond-pattern nitrile protective gloves and surgical gloves, expanding its product categories to cover 9 major categories and over 60 product series [170]. Market Strategy and Expansion - In 2023, the company aims to enhance customer service, improve organizational efficiency, and increase market share by developing new domestic and international customers [6]. - The company has established a comprehensive sales and marketing network, serving over 10,000 customers in more than 120 countries and regions [44]. - The company has implemented five rounds of restricted stock incentive plans since its A-share listing in 2017, benefiting approximately 1,490 individuals [64]. - The company is focusing on strengthening its global marketing network and increasing investment in online channels [68]. Challenges and Adaptations - The company has faced challenges in 2022, including price declines and supply-demand imbalances, but has focused on cost reduction and efficiency improvements [167]. - The company has implemented energy-saving measures, reducing energy consumption through various optimization techniques [43]. Financial Management - The company's cash and cash equivalents at the end of the period amounted to ¥5,033,125,320, an increase from ¥5,002,855,287 at the beginning of the period [192]. - The total amount of bank deposits increased to ¥5,013,056,455 from ¥4,980,979,160, indicating a growth in liquidity [192]. - The accounts receivable amounted to ¥603,276,269, with a bad debt provision of ¥49,761,682, representing a provision ratio of 8.25% [196]. - The company has maintained a consistent corporate income tax rate of 15% for its subsidiaries in China, as per the relevant tax regulations [189].

Market Overview - The global disposable glove market reached a sales volume of 417 billion pieces in 2017, with the medical-grade glove market accounting for approximately 270 billion pieces and non-medical-grade gloves at 147 billion pieces. By 2020, the market is expected to grow to 531 billion pieces, reflecting a compound annual growth rate (CAGR) of 8.39% over three years [3][4]. - The company currently produces around 13 billion gloves annually, capturing about 3% of the global market share, with plans to increase this to 10% within five years through expansion in Anhui and Vietnam [4]. Competitive Landscape - The nitrile glove market is dominated by manufacturers from Malaysia, creating a stable competitive environment. The company has developed competitive advantages in terms of industrial support and labor quality compared to these established players [4][5]. - In the domestic market, major competitors include Blue Sail Medical (18 billion gloves), Zhonghong Medical (7 billion gloves), and Shijiazhuang Hongrui, with the company leveraging new production lines for enhanced automation and efficiency [5][6]. Financial Impact of Trade Policies - The company has experienced a slowdown in capacity expansion due to the US-China trade war, with over 95% of sales revenue derived from overseas clients. However, the impact on performance has been minimal, as most products are not subject to additional tariffs [6][7]. - The company plans to mitigate risks from potential trade escalations by increasing market development in Europe, Japan, and emerging markets in the Middle East and South America [7]. Production and Investment - The company’s production capacity has been operating at approximately 100%, with ongoing projects including an IPO fundraising initiative aimed at producing 5.88 billion high-end medical gloves annually [8][9]. - Recent investments include the establishment of 15 nitrile production lines and 20 PVC production lines, with additional capacity planned for Anhui [8][9]. Regulatory and Market Entry Barriers - The medical glove market has high entry barriers due to necessary certifications such as the FDA 510K and EU CE certifications, alongside significant capital and technical requirements for new entrants [9][10]. - The company maintains a competitive edge through advanced technology and production efficiency, which are critical in a capital-intensive industry [10]. Financial Performance - The company's return on equity (ROE) was 15.19% in 2018, slightly down from 18.25% in 2017, primarily due to rapid net asset growth despite stable profitability [10][11]. - The company’s product pricing is influenced by raw material costs, energy prices, and currency fluctuations, with stable prices for nitrile gloves and lower prices for PVC gloves expected to persist [7][11]. Non-Medical Product Growth - The company has also seen growth in its non-medical product lines, including wheelchairs and thermal therapy products, with wheelchair production reaching 350,000 units in 2018 [11]. - Plans for 2019 include the development of a smart medical device research and marketing center, with an initial production capacity of 100,000 electric wheelchairs [11].